GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (BOM:509079) » Definitions » EV-to-EBITDA

Gufic Biosciences (BOM:509079) EV-to-EBITDA : 28.06 (As of May. 25, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Gufic Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gufic Biosciences's enterprise value is ₹40,926 Mil. Gufic Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was ₹1,459 Mil. Therefore, Gufic Biosciences's EV-to-EBITDA for today is 28.06.

The historical rank and industry rank for Gufic Biosciences's EV-to-EBITDA or its related term are showing as below:

BOM:509079' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.12   Med: 17.16   Max: 35.13
Current: 28.06

During the past 13 years, the highest EV-to-EBITDA of Gufic Biosciences was 35.13. The lowest was 6.12. And the median was 17.16.

BOM:509079's EV-to-EBITDA is ranked worse than
77.14% of 735 companies
in the Drug Manufacturers industry
Industry Median: 13.73 vs BOM:509079: 28.06

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-25), Gufic Biosciences's stock price is ₹380.55. Gufic Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹8.170. Therefore, Gufic Biosciences's PE Ratio (TTM) for today is 46.58.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Gufic Biosciences EV-to-EBITDA Historical Data

The historical data trend for Gufic Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gufic Biosciences EV-to-EBITDA Chart

Gufic Biosciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.63 13.56 16.46 15.59 21.54

Gufic Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.46 21.54 23.47 28.18 31.35

Competitive Comparison of Gufic Biosciences's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's EV-to-EBITDA falls into.


;
;

Gufic Biosciences EV-to-EBITDA Calculation

Gufic Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=40926.033/1458.637
=28.06

Gufic Biosciences's current Enterprise Value is ₹40,926 Mil.
Gufic Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,459 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gufic Biosciences  (BOM:509079) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Gufic Biosciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=380.55/8.170
=46.58

Gufic Biosciences's share price for today is ₹380.55.
Gufic Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8.170.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Gufic Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gufic Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gufic Biosciences Business Description

Traded in Other Exchanges
Address
SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.

Gufic Biosciences Headlines

No Headlines